References
  1. Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application . Nat Rev Genet. 2015;16(1):45-56.
  2. Pereira SV, Ribeiro JD, Ribeiro AF, Bertuzzo CS, Marson FAL.Novel, rare and common pathogenic variants in the CFTR gene screened by high-throughput sequencing technology and predicted by in silico tools . Sci Rep. 2019;17(9):1-16.
  3. Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, et al. Recommendations for the classification of diseases as CFTR related disorders . J Cyst Fibros. 2011;10(Suppl 2):86-102.
  4. Justicia JL, Sole ̵́ A, Quintana-Gallego E, Gartner S, de Gracia J,Prados C, Ma ̵́iz L. Management of pulmonary exacerbations in cystic fibrosis: still an unmet medical need in clinical practice . Expert Rev Respir Med. 2015;9(2):183–94.
  5. Illing EA, Woodworth BA. Management of the upper airway in cystic fibrosis . Curr Opin Pulm Med. 2014;20(6):623–31.
  6. Cipolli M, Castellani C, Wilcken B, Massie J, McKay K, GrucaM, et al.Pancreatic phenotype in infants with cystic fibrosis identified by mutation screening . Arch Dis Child. 2007;92(10):842–84.
  7. Park HW, Nam JH, Kim JY, Namkung W, Yoon JS, Lee JS, et al.Dynamic regulation of CFTR bicarbonate permeability by Cl- and its role in pancreatic bicarbonate secretion . Gastroenterology. 2010;139(2):620-31.
  8. Moran A, Pillay K, Becker D, Granados A, Hameed S, Acerini CL.ISPAD Clinical Practice Consensus Guidelines 2018: Management of cystic fibrosis-related diabetes in children and adolescents . Pediatr Diabetes. 2018;19(Suppl 27):64-74.
  9. Dupuis A, Keenan K, Ooi CY, Dorfman R, Sontag MK, Naehrlich L, et al.Prevalence of meconium ileus marks the severity of mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene . Genet Med. 2016;18(4):333–40.
  10. Flass T, Narkewicz MR. Cirrhosis and other liver disease in cystic fibrosis . J Cyst Fibros. 2013;12(2):116–24.
  11. Dayangaç D, Erdem H, Yilmaz E, Şahin A, Sohn C, Özgüç M, et al.Mutations of the CFTR gene in Turkish patients with congenital bilateral absence of the vas deferens . Hum Reprod. 2004;19(5):1094-100.
  12. Costes B, Girodon E, Ghanem N, Flori E, Jardin A, Soufir JC et al.Frequent occurrence of the CFTR intron 8 (TG)n 5T allele in men with congenital bilateral absence of the vas deferens . Eur J Hum Genet. 1995;3(5):285–93.
  13. Clarke LA, Sousa L, Baretto C, Amaral MD. Changes in nasal transcriptome of native nasal epithelium expressing F508del-CFTR and intersecting data from comparable studies . Respir Res. 2013;14(38):1- 19.
  14. Clarke LA, Botelho HM, Sousa L, Falcao AO, Amaral MD.Transcriptome meta-analysis reveals common differential and global gene expression profiles in cystic fibrosis and other respiratory disorders and identifies CFTR regulators . Genomics. 2015;106(5):268-77.
  15. Wright JM, Merlo CA, Reynolds JB, Zeitlin PL, Garcia JG, Guggino WB, et al. Respiratory epithelial gene expression in patients with mild and severe cystic fibrosis lung disease . Am J Respir Cell Mol Biol. 2006;35(3):327-36.
  16. Mekus F, Ballmann M, Bronsveld I, Bijman J, Veeze H, Tümmler B.Categories of delta F508 homozygous cystic fibrosis twin and sibling pairs with distinct phenotypic characteristics . Twin Res. 2000;3(4):277– 93.
  17. Terlizzi V, Lucarelli M, Salvatore D, Angioni A, Bisogno A, Braggion C, et al. Clinical expression of cystic fibrosis in a large cohort of Italian siblings . BMC Pul Med. 2018;18(1):1-8.
  18. Kormann MSD, Dewerth A, Eichner F, Baskaran P, Hector A, Regamey N, et al. Transcriptomic profile of cystic fibrosis patients identifies type I interferon response and ribosomal stalk proteins as potential modifiers of disease severity . PLoS One. 2017;12(8):1-13.
  19. Ogilvie V, Passmore M, Hyndman L, Jones L, Stevenson B, Wilson A, et al. Differential global gene expression in cystic fibrosis nasal and bronchial epithelium . Genomics. 2011;98(5):327-36.
  20. Cutting GR. Modifier genes in Mendelian disorders: the example of cystic fibrosis . Ann N Y Acad Sci. 2010;1214(1):57-69.
  21. Monin L, Gaffen SL. IL-17 family cytokines: signaling mechanisms, biological activities and therapeutic implications . Cold Spring Harb Perspect Med. 2018;10(4):1-24.
  22. Hobbs CA, Da Tan C, Tarran R. Does epithelial sodium channel hyperactivity contribute to cystic fibrosis lung disease? J Physiol. 2013;591(18):4377-87.
  23. Singh AK, Riederer B, Krabbenhöft A, Rausch B, Bonhagen J, Lehmann U, et al. Differential roles of NHERF1, NHERF2, and PDZK1 in regulating CFTR-mediated intestinal anion secretion in mice . J Clin Invest. 2009;119(3):540-50.
  24. Ganeshan R, Di A, Nelson DJ, Quick MW, Kirk KL. The interaction between syntaxin 1A and cystic fibrosis transmembrane conductance regulator Cl- channels is mechanistically distinct from syntaxin 1A- SNARE interactions . J Biol Chem. 2003;278(5):2876-85.
  25. Boyaka E, Di A, Chang SY, Naren AP, Tousson A, Nelson DJ, et al.CFTR chloride channels are regulated by a SNAP-23/syntaxin 1A complex . Proc Natl Acad Sci USA. 2002;99(19):12477-82.
  26. Chu CY, Qiu X, Wang L, Bhattacharya S, Lofthus G, Corbett A, et al.The Healthy Infant Nasal Transcriptome: A Benchmark Study . Sci Rep. 2016;23(6):1-10.
  27. Ideozu JE, Rangaraj V, Abdala-Valencia H, Zhang X, Kandpal M, Sala MA, et al. Transcriptional consequences of impaired immune cell responses induced by cystic fibrosis plasma characterized via dual RNA sequencing . BMC Med Genomics. 2019;12(1):1-16.
  28. Tang AC, Saferali A, He G, Sandford AJ, Strug LJ, Turvey SE.Endoplasmic Reticulum Stress and Chemokine Production in Cystic Fibrosis Airway Cells: Regulation by STAT3 Modulation . J Infect Dis. 2017;215(2):293-302.
  29. Scambler T, Griffiths HJ, Reyna S, Pathak S, Wong C, Holbrook J, et al. ENaC-mediated sodium influx drives NLRP3 inflammasome- dependent autoinflammation in cystic fibrosis . eLife. 2019;8:e49248
  30. McElvaney OJ, Zaslona Z, Becker-Flegler K, Palsson-McDermott EM, Boland F, Gunaratnam C, et al. Specific Inhibition of the NLRP3 Inflammasome as an Anti-Inflammatory Strategy in Cystic Fibrosis .Am J Respir Crit Care Med. 2019;200(11):1381-91.
  31. Yamagishi S, Matsui T. Role of receptor for advanced glycation end products (RAGE) in liver disease . Eur J Med Res. 2015;20(1):1-7.
  32. Stonebraker JR, Ooi CY, Pace RG, Corvol H, Knowles MR, Durie PR, et al. Features of severe liver disease with portal hypertension in patients with cystic fibrosis . Clin Gastroenterol Hepatol. 2016; 14(8):1207-15.
  33. Paranjapye A, Ruffin M, Harris A, Corvol H. Genetic Variation in CFTR and Modifier Loci May Modulate Cystic Fibrosis Disease Severity . J Cyst Fibros. 2020;19(Suppl 1):10-14.
  34. Debray D, Corvol H, Housset C. Modifier genes in cystic fibrosis-related liver disease. Curr Opin Gastroenterol.2019;35(2):88-92.